References
- Lockhart S, Plunkett W, Jeha S, et al. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. J Clin Oncol 1994; 12: 587–595
- Mitchell E P, Glicksman A S, Schein P S. Acute and late effects of Canpolat et al. cancer therapy and their management. Medical Oncology2nd ed, P S Calabresi, P S Schein. McGraw-Hill, New York 1993; 345–369
- Gottesman M M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427
- Mirro J, Crom W, Santana V M, et al. AML Trials at St. Jude Children's Research Hospital. Acute Myelogenous Leukemia: Progress and Controversies. Wiley-Liss, New York 1990; 219–227
- Pinkel D. Lessons from 20 years of curative therapy of childhood acute leukemia. Br J Cancer 1992; 65: 145–153
- Boulad F, Kernan N A. Treatment of childhood acute nonlym-phoblastic leukemia: A review. Cancer Invest 1993; 11: 534–553
- Odom L. Pediatric acute non-lymphocytic leukemia. Hematology, Basic Principles and Practice2nd ed, R Hoffman, E J Benz, S J Shattil, B Furie, H J Cohen, L E Silberstein. Churchill Livingstone, New York 1994; 748–759